Welcome to BioSeeker Group!

Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5657
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides.

    To find out more about Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part II: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
4SC
7TM Pharma
AB Science
Abbott
Abiogen
Acceleron Pharma
Access
ACT Biotech
Active Biotech
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affymax
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alethia Biotherapeutics
Allist Pharmaceuticals
Allostera
Allosterix
Alnylam
AlphaVax
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anchor Therapeutics
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
AplaGen Biopharmaceuticals
Apogee Biotechnology
ApopLogic Pharmaceuticals
Arana Therapeutics
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
Avila Therapeutics
Bavarian Nordic
Baxter International
Bayer
Benitec
Berkeley Lab
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
Biokine Therapeutics
Bionovo
Biotecnol
Biotica Technology
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
Catalyst Biosciences
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Cellmid
Cephalon
CerRx
ChemoCentryx
Chemokine Therapeutics
Chiasma
China Sky One Medical
Choongwae
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinical Data
Clinuvel
CompleGen
Compugen
CoNCERT Pharmaceuticals
Cue Biotech
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cytochroma
Cytokine PharmaSciences
Cytopia
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Digna Biotech
Dongkook Pharm
Dyax
Eisai
Elara Pharmaceuticals
Eli Lilly
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Five Prime Therapeutics
Formula Pharmaceuticals
Galapagos
Galena Biopharma
GammaCan
Generex
Genmab
GENova Biotherapeutics
Genovax
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
GP Pharm
GPC Biotech
Green Cross
Gryphon Therapeutics
Hanmi
Hoffmann-La Roche
Hutchison China MediTech
Hy BioPharma
Hypha Discovery
Idera Pharmaceuticals
ImClone Systems
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunotope
ImmuPharma
Incozen Therapeutics
Incyte Corporation
Inhibiton Therapeutics
Innovive
Inovio
Insmed
Insys Therapeutics
Intellikine
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAEL-GemVax
KAI Pharmaceuticals
KaloBios
Kalypsys
Karus Therapeutics
Karyon-CTT
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirax
Kirin Pharma
Kringle Pharma
KuDOS
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Lexicon Pharmaceuticals
Ligand
Lorus Therapeutics
Marillion Pharmaceuticals
Marina Biotech
MAT Biopharma
MaxoCore Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Molecular LogiX
MolMed
Morvus Technology
Myrexis
Nano Terra
Nektar Therapeutics
Nemod Biotherapeutics
Nerviano Medical Sciences
Neurobiological Technologies
NewSouth Innovations
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
NovaLead
Novartis
Novelix
Novogen
Noxxon
NPS Pharmaceuticals
Oasmia
Oncalis
Onconova
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Pathway Therapeutics
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Portola Pharmaceuticals
Proacta
Progen
Progenics Pharmaceuticals
Protagonist
Protein Sciences
Protgen
Provid
PTC Therapeutics
Q Chip
QLT
Quantum Pharmaceuticals
Raptor Pharmaceutical
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Rexahn
Rigel
Samtheo Biopharma
Sanofi
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
SciClone Pharmaceuticals
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
Serometrix
SGX Pharmaceuticals
Shionogi
Shire
Silence Therapeutics
Simcere Pharmaceuticals
Soligenix
Spear Therapeutics
Spectrum Pharmaceuticals
SRI International
Stainwei Biotech
Sunesis
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
SynDevRx
Tactic Pharma
Taiho
Takeda
Tamir Biotechnology
Targa Therapeutics
TargeGen
Tau Therapeutics
TauTaTis
TCD Pharma
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
TransTech Pharma
UCB
Unigene
United Biomedical
VasGene Therapeutics
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Wilex
VioQuest
ViroMed
Wyeth
Xcovery
Xencor
Xerion
Xigen
YM BioSciences
Zelos Therapeutics
Zensun
Zenyaku Kogyo
A Shortlist of Drugs Included are:
A6
abarelix
ABT-510
AC-480
AE-37
AEZS-108
AF-802
afamelanotide
afatinib
aflibercept
alvocidib
AMG-386
angiopep+paclitaxel
Angiozyme
apatinib
AR-42
ARQ-197
AT-7519
AT-9283
atrasentan
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
bevacizumab
BEZ-235
BGT-226
BI-811283
BIBF-1120
BMS-690514
BMS-754807
BMS-777607
bosutinib
brivanib alaninate
Cabozantinib
CAL-101
CBP-501
CC-223
cediranib
cilengitide
corticorelin acetate
crizotinib
dacomitinib
danusertib
dasatinib
deslorelin
DI-17E6
dinaciclib
dovitinib lactate
E-75
E-7820
emepepimut-S
endostatin
endoxifen
ENMD-2076
enzastaurin hydrochloride
EP-100
erlotinib
everolimus
Exherin
foretinib
fosbretabulin tromethamine
fostamatinib disodium
FPI-01
gefitinib
GliaAtak
goserelin
GSK-2118436
GT-111
GV-1001
GX-301
HBP-347
Her-2/Neu peptides
histrelin
IC-83
icrucumab
idronoxil
imatinib mesilate
imMucin
INCB-028060
INSM-18
intetumumab
IPP-204106
ISA-P53-01
JI-101
kahalalide F
KD032
KX2-391
lanreotide
lapatinib ditosylate
lenvatinib
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
linifanib
linsitinib
LY-2090314
LY-2275796
masitinib
MDX-1379
MGCD-265
midostaurin
MK-1775
MKC-1
MLN-8237
MM-111
motesanib diphosphate
muparfostat (IV)
MVA-BN Her-2 vaccine
NAFB001
neratinib
netupitant
NGR-TNF
nilotinib
NPB-001-056
octreotide
octreotide, LAR
ON-01910
onartuzumab
OSI-027
OTS-102
ozarelix
P276-00
paclitaxel
PancAtak
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
PD-0332991
pegdinetanib
perifosine
PF-4856884
PHA-848125AC
plitidepsin
polyclonal antibody stimulator
ponatinib
ProstAtak
PTC-299
PX-866
quinacrine
quizartinib dihydrochloride
RAF-265
ramucirumab
regorafenib
ridaforolimus
rilotumumab
rindopepimut
romurtide
ruxolitinib
RX-0201-N
SCH-900776
seliciclib
sirolimus
sorafenib tosylate
sotatercept
ß-lapachone
SU-6668
sunitinib malate
Survivac
talactoferrin alfa
talmapimod
tandutinib
TAS-102
tasquinimod
TB-403
telatinib
temsirolimus
Tenarad
terameprocol
thymalfasin
tipifarnib
tivozanib
TM-30339
TRC-105
triciribine phosphate
vandetanib
vapreotide, immediate-release
varlitinib
vemurafenib
vismodegib
vitespen
volasertib
volociximab
vosaroxin
VX-001
XL-147
XL-184
XL-281
XL-413
XL-647
XL-765

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides.
    To find out more about Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lymphoma, Angiogenesis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Learn More


Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Target Atlas in Peritoneal Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More


Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update
BioSeeker Group have identified 488 companies plus partners who are today developing 739 focal adhesion targeting drugs in 2727 developmental projects in cancer across 268 different targets. In addition, there are 5 suspended drugs and another 315 drugs where development has been ceased. Learn More